Observational studyBiomarkers in medicine2022
Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies.
Observational study in Biomarkers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
A Diagnostic Test for Dementia With Lewy Bodies
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Cutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia.Annals of clinical and translational neurology · 2026Article
- The Syn-sleep trial protocol: detection of cutaneous phosphorylated alpha-synuclein in REM sleep behavior disorder.Biomarkers in medicine · 2026Article
- Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Complementary biomarkers or conflicting signals? DaT SPECT and synuclein skin biopsy in parkinsonian syndromes.BMJ neurology open · 2026Article
- Clinical utility of skin biopsy detection of phosphorylated alpha-synuclein in an outpatient practice.Frontiers in neurology · 2026Article
- Prediction of α-synuclein seed amplification assay positivity in remotely followedJournal of clinical and translational science · 2026Article
- Exploring the skin as an open window onto neurodegenerative diseases.Translational neurodegeneration · 2025Review
- The future of Parkinson's care: a need to expand access.Frontiers in neurology · 2025Article
- Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- A cross-database bibliometric analysis of rapid eye movement sleep behavior disorder in Parkinson's disease research.Frontiers in aging neuroscience · 2025Article
- Early diagnosis of Parkinson's disease: biomarker study.Frontiers in aging neuroscience · 2025Review
- Lewy Body Dementia.Continuum (Minneapolis, Minn.) · 2024Review
- Review
- Navigating the Neurobiology of Parkinson's: The Impact and Potential of α-Synuclein.Biomedicines · 2024Review
- Lewy body dementia: Overcoming barriers and identifying solutions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions.Frontiers in neurology · 2024Review
- Clinical utility of synuclein skin biopsy in the diagnosis and evaluation of synucleinopathies.Frontiers in neurology · 2024Article
- Multiple system atrophy: Diagnostic challenges and a proposed diagnostic algorithm.Clinical parkinsonism & related disorders · 2024Review
- Recent updates in autonomic research: orthostatic hypotension and cognitive function in Parkinson disease and multiple system atrophy, the skin as a window into synuclein pathology, and RFC1 repeat expansions in hereditary sensory autonomic neuropathies.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023Article
- Fluid and Biopsy Based Biomarkers in Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
Finding an easily accessible and reliable tool to diagnose the diseases collectively defined as 'synucleinopathies' is an urgent, unmet priority. The synucleinopathies include Parkinson's disease, multiple system atrophy, pure autonomic failure and dementia with Lewy bodies. There are millions of people who have a diagnosis of a synucleinopathy, with more diagnosed every year. With accessibility, ease of implementation, consistently high sensitivity (>80%) and specificity approaching 100%, skin biopsy has great potential as the clinical test of choice for the diagnosis of synucleinopathies. The large, multi-center Synuclein-One study will determine the sensitivity, specificity, accuracy and precision of α-synuclein detection within punch skin biopsies in patients with clinically established synucleinopathies using standardized, robust methods suitable for large-scale analysis. Clinical Trial Registration: NCT04700722 (ClinicalTrials.gov).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.